Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage ADC biotech with ValiLinker site-specific conjugation technology; VLT-03 in Phase I for solid tumors and VLT-01 for brain metastases with $20.5M raised.
Valink Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumors using its proprietary ValiLinker technology — a site-specific conjugation platform that precisely attaches cytotoxic payloads to antibodies at defined positions, improving ADC stability, homogeneity, and therapeutic index compared to conventional random-conjugation approaches. Founded in 2020 and headquartered in Houston, Texas, Valink raised $20.5 million total including an $11.8 million Pre-Series A in October 2025 to advance its pipeline into clinical trials.\n\nValink's pipeline centers on VLT-03 (targeting solid tumors in Phase I trials) and VLT-01 (targeting solid tumors with brain metastases, addressing the significant unmet need in CNS-penetrating oncology therapeutics). The ValiLinker conjugation technology enables precise drug-to-antibody ratios and reduces off-target toxicity that has historically limited ADC tolerability — the platform differentiates Valink from earlier ADC developers by addressing the conjugation chemistry precision that drives therapeutic index improvements in this modality.\n\nIn 2025, Valink competes in the ADC space with Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), Daiichi Sankyo (partnered with AstraZeneca), and numerous clinical-stage biotech ADC developers. ADC development has become one of the most active areas in oncology after the commercial success of Enhertu (trastuzumab deruxtecan) demonstrated the potential of the modality. Valink's site-specific conjugation differentiation targets the technical limitations of first-generation ADCs that created toxicity issues. The 2025-2026 strategy focuses on Phase I dose escalation for VLT-03, building clinical proof-of-concept for the ValiLinker platform, and positioning for partnership or licensing discussions with large pharma.
Kindful, nonprofit donor management/CRM platform (acquired by Bloomerang 2020), 1,000+ nonprofit customers, cloud-based fundraising software, online donation forms, donor analytics, email marketing, integrated with QuickBooks/Mailchimp, now part of Bloomerang suite
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid-sized nonprofits who need affordable, user-friendly software to organize donor data, process contributions, and measure fundraising effectiveness. Kindful provides tools for online giving, email marketing, event management, donor segmentation, and reporting that help nonprofits build stronger relationships with supporters, streamline fundraising operations, and increase donations while reducing administrative burden.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.